Principal Financial Group Inc. raised its stake in Natera, Inc. (NASDAQ:NTRA) by 49.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 168,581 shares of the medical research company’s stock after purchasing an additional 55,894 shares during the period. Principal Financial Group Inc. owned approximately 0.32% of Natera worth $2,173,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of NTRA. Virtu KCG Holdings LLC bought a new stake in Natera in the 2nd quarter valued at $126,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in Natera in the 2nd quarter valued at $151,000. Goldman Sachs Group Inc. lifted its holdings in shares of Natera by 45.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 17,386 shares of the medical research company’s stock worth $154,000 after acquiring an additional 5,417 shares during the period. Voya Investment Management LLC lifted its holdings in shares of Natera by 17.8% during the 2nd quarter. Voya Investment Management LLC now owns 14,663 shares of the medical research company’s stock worth $159,000 after acquiring an additional 2,212 shares during the period. Finally, Wells Fargo & Company MN lifted its holdings in shares of Natera by 2.8% during the 2nd quarter. Wells Fargo & Company MN now owns 18,031 shares of the medical research company’s stock worth $195,000 after acquiring an additional 491 shares during the period. 66.19% of the stock is owned by hedge funds and other institutional investors.
NTRA has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Natera from a “sell” rating to a “buy” rating and set a $15.00 price objective for the company in a report on Wednesday, October 11th. Robert W. Baird reaffirmed a “buy” rating on shares of Natera in a report on Tuesday, October 24th. Canaccord Genuity reaffirmed a “buy” rating and set a $15.00 price objective on shares of Natera in a report on Tuesday, November 14th. Morgan Stanley reaffirmed an “overweight” rating and set a $16.00 price objective (up from $13.00) on shares of Natera in a report on Friday, October 6th. Finally, BidaskClub raised shares of Natera from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $15.00.
Natera (NASDAQ:NTRA) last released its quarterly earnings data on Wednesday, November 8th. The medical research company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The business had revenue of $56.66 million for the quarter, compared to the consensus estimate of $55.31 million. Natera had a negative return on equity of 197.09% and a negative net margin of 62.34%. Natera’s revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the business posted ($0.50) earnings per share. equities research analysts expect that Natera, Inc. will post -2.15 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.com-unik.info/2017/12/12/principal-financial-group-inc-raises-holdings-in-natera-inc-ntra.html.
What are top analysts saying about Natera Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Natera Inc. and related companies.